SR9243

CAS No. 1613028-81-1

SR9243( SR9243 | SR-9243 | SR 9243. )

Catalog No. M12335 CAS No. 1613028-81-1

SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 29 In Stock
5MG 46 In Stock
10MG 65 In Stock
25MG 113 In Stock
50MG 177 In Stock
100MG 327 In Stock
200MG 518 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR9243
  • Note
    Research use only, not for human use.
  • Brief Description
    SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction.
  • Description
    SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction; shows anticancer activity and selectively targets the warburg effect and lipogenesis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SR9243 | SR-9243 | SR 9243.
  • Pathway
    Nuclear Receptor/Transcription Factor
  • Target
    LXR
  • Recptor
    LXR
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1613028-81-1
  • Formula Weight
    626.62
  • Molecular Formula
    C31H32BrNO4S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMF: 98 mg/mL warming (156.39 mM)
  • SMILES
    O=S(C1=C(C)C=C(C)C=C1C)(N(CCC2=CC=CC(Br)=C2)CC3=CC=C(C4=CC=CC(S(=O)(C)=O)=C4)C=C3)=O
  • Chemical Name
    N-(3-bromophenethyl)-2,4,6-trimethyl-N-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Flaveny CA, et al. Y Cell. 2015 Jun 24. pii: S1535-6108(15)00183-X.
molnova catalog
related products
  • GW3965

    A potent, selective, orally active LXR agonist that recruits the steroid receptor coactivator 1 to human LXRα in a cell-free ligand-sensing assay with an EC50 of 125 nM.

  • BMS-779788

    A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ.

  • LXR-623

    A clinically viable, highly brain-penetrant LXRα-partial/LXRβ-full agonist with binding Ki of 33 nM/248 nM.